Why the study?
Does admission hyperglycemia predict impaired coronary flow (measured by TIMI frame count and no-reflow) in patients with STEMI undergoing primary PCI?
Does admission hyperglycemia predict impaired coronary flow (measured by TIMI frame count and no-reflow) in patients with STEMI undergoing primary PCI?
Admission hyperglycemia in STEMI patients undergoing primary PCI is an independent predictor of impaired coronary flow, as evidenced by higher TIMI frame counts and increased no-reflow frequency.
Admission hyperglycemia may predict impaired flow in STEMI PCI; leaves open whether glucose control improves outcomes.
We evaluated the relationship between admission blood glucose levels and estimated coronary flow by the thrombolysis in myocardial infarction (TIMI) frame count (TFC) method in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). The TFC of 121 consecutive patients with STEMI were evaluated after pPCI. Patients with admission glucose levels > 198 mg/dL (11 mmol/L) were defined as hyperglycemic. Hyperglycemia was observed in 36 (29.8%) patients. The TFC was significantly higher in patients with hyperglycemia (70.75 [10-96] vs 56.87 [8-100], P = .04). No-reflow frequency was higher in the hyperglycemia group (44.4% vs 23.5%, P = .02). In multivariate linear regression analysis admission glucose was an independent predictor of high TFC (B = 0.21, P = .02). Our findings suggest that admission blood glucose is a predictor of TFC which reflects coronary blood flow.
No takes yet. Share an insight, caveat, or question.
Yıldız et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: